Longitudinal Multi-Omic Characterization of Patient Responses to Neoadjuvant HER2-Targeted Therapy
Documentation files
Documentation files
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
Yes
Type of personal data:
The dataset does not contain direct identifiers such as names, social security numbers, or contact details. Each patient is represented by a specific ID. These specific IDs are pseudonymized and cannot be used to identify individual patients. Linkage to individual identities is only possible by the local principal investigator and designated site staff through site-specific keys, which are not shared. The metadata includes sampling time, treatment arm, which are indirect identifiers.
Code key exists:
Yes
Sensitive personal data:
Yes
Citation:
Language:
Method and outcome
Method and outcome
Population:
Time method:
Study design:
- Experimental study
Data format/data structure:
Administrative information
Administrative information
Responsible department/unit:
Department of Oncology-Pathology [K7]
Ethical Review
Ethical Review
Reviewer:
- Stockholm Ethical Review Board
Registration number:
dnr 2014/1465-31/10
Registration number:
EudraCT-number: 2014-000808-10
Ethical review information:
Registration number:
EUCT number:2023-508411-23-00
Funding
Funding
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROR
Award number:
2018-02398_VR
Award title:
Optimizing treatment in HER2 positive breast cancer through insights in tumor biology
Funding information:
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROR
Award number:
2021-03061_VR
Award title:
Integrative digital diagnostics for therapy optimization in early breast cancer
